Headlands Technologies LLC Grows Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Key Points

• Headlands Technologies LLC increased its ownership in Recursion Pharmaceuticals by 85.7%, acquiring an additional 76,536 shares in the first quarter, bringing its total to 165,850 shares valued at approximately $877,000.
• Recursion Pharmaceuticals reported a negative EPS of ($0.41) for the latest quarter, missing expectations, even as the company saw a 33.3% increase in revenue year-over-year to $19.1 million.
• Wall Street analysts have a consensus rating of "Hold" for Recursion Pharmaceuticals, with target prices ranging from $5.00 to $8.00, indicating cautious optimism about its financial outlook.

Headlands Technologies LLC grew its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 85.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 165,850 shares of the company's stock after purchasing an additional 76,536 shares during the period. Headlands Technologies LLC's holdings in Recursion Pharmaceuticals were worth $877,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. GAMMA Investing LLC boosted its position in Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares in the last quarter. NewEdge Advisors LLC boosted its position in Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after purchasing an additional 2,387 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Recursion Pharmaceuticals in the 4th quarter worth approximately $54,000. Rathbones Group PLC purchased a new stake in Recursion Pharmaceuticals in the 4th quarter worth approximately $69,000. Finally, San Luis Wealth Advisors LLC purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth approximately $54,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on RXRX. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Morgan Stanley began coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 target price for the company. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $7.00.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded up $0.03 during mid-day trading on Tuesday, hitting $5.32. The stock had a trading volume of 8,925,172 shares, compared to its average volume of 25,057,135. The firm's 50 day moving average is $5.42 and its 200 day moving average is $5.87. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -3.00 and a beta of 0.93.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%. The company had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. During the same period last year, the business earned ($0.40) earnings per share. The firm's revenue was up 33.3% compared to the same quarter last year. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.